This is a randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of triplet therapy with bempedoic acid (ETC-1002) 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg in patients with elevated LDL-C.
The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.